4//SEC Filing
Nichols Weston 4
Accession 0000902664-25-004379
CIK 0001789972other
Filed
Oct 9, 8:00 PM ET
Accepted
Oct 10, 6:58 PM ET
Size
12.5 KB
Accession
0000902664-25-004379
Insider Transaction Report
Form 4
Lynx1 Capital Management LP
10% Owner
Transactions
- Purchase
Common Stock
2025-10-09$6.70/sh+626,043$4,191,859→ 8,271,786 total(indirect: See footnote) - Purchase
Common stock, $0.0001 par value per share ("Common Stock")
2025-10-08$6.46/sh+556,300$3,593,698→ 7,645,743 total(indirect: See footnote) - Purchase
Common Stock
2025-10-10$7.36/sh+277,298$2,041,385→ 8,549,084 total(indirect: See footnote)
Nichols Weston
10% Owner
Transactions
- Purchase
Common stock, $0.0001 par value per share ("Common Stock")
2025-10-08$6.46/sh+556,300$3,593,698→ 7,645,743 total(indirect: See footnote) - Purchase
Common Stock
2025-10-09$6.70/sh+626,043$4,191,859→ 8,271,786 total(indirect: See footnote) - Purchase
Common Stock
2025-10-10$7.36/sh+277,298$2,041,385→ 8,549,084 total(indirect: See footnote)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.60 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
- [F2]The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.60 to $6.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.87 to $7.46 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
Documents
Issuer
Cullinan Therapeutics, Inc.
CIK 0001789972
Entity typeother
Related Parties
1- filerCIK 0001746376
Filing Metadata
- Form type
- 4
- Filed
- Oct 9, 8:00 PM ET
- Accepted
- Oct 10, 6:58 PM ET
- Size
- 12.5 KB